Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



VENTUREPHARM LABORATORIES LIMITED

萬全科技藥業有限公司* (incorporated in the Cayman Islands with limited liability) (Stock Code:8225)

FURTHER POSTPONMENT OF BOARD MEETING, DELAY IN PUBLICATION OF ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2011 AND THE FIRST QUARTERLY RESULTS ENDED 31 MARCH 2012 AND THE INTERIM RESULTS ENDED 30 JUNE 2012 AND THE THIRD QUARTERLY RESULTS ENDED 30 SEPTEMBER 2012 AND SUSPENSION OF TRADING

Reference is made to the meeting (the "Board meeting") of the board (the "Board") of directors (the "directors") of Venturepharm Laboratories Limited (the "Company") originally dated on 19 November 2012, for the purpose of considering and approving, among other matters, the audited consolidated financial results of the company and its subsidiaries for the year ended 31 December 2011(the "Results"), the unaudited results of the Company and its subsidiaries for the three months ended 31 March 2012 and the draft announcement in respect of the results to be published on the GEM website, the unaudited results of the Company and its subsidiaries for the results to be published on the GEM website, the unaudited results of the Company and its subsidiaries for the results to be published on the GEM website, the unaudited results of the Company and its subsidiaries for the results to be published on the GEM website, the unaudited results of the Company and its subsidiaries for the results to be published on the GEM website, the unaudited results of the Company and its subsidiaries for the results to be published on the GEM website, the unaudited results of the Company and its subsidiaries for the nine months ended 30 September 2012 and the draft announcement in respect of the results to be published on the GEM website.

As our auditors need more time to complete the auditing work, therefore the meeting will be postponed twelve working days to 6 December 2012 at 10:00 a.m..Accordingly, there will be a further delay in the publication of the annual results announcement for the FY 2011, and there also will be a further delay in the publication of the first quarterly results and the interim results and the third quarterly results of FY2012. At the request of the company, trading in the securities of the company on the Stock Exchange has been suspended from 9:00 a.m. on 2 April 2012, and will remain suspended until the release of an announcement relating to the publication of its annual results and dispatch of its annual report for the year ended 31 December 2011.

> By order of the Board Venturepharm Laboratories Limited William Xia Guo

Chairman

Beijing, the PRC, 16 November 2012

* For identification purpose only

As at the date of this announcement, the Board comprises two executive directors, being Mr. William Xia Guo and Dr. Maria Xue Mei Song; three non-executive directors, being Mr. Feng Tao, Mr. Li Jin Liang and Dr. Nathan Xin Zhang; and three independent non-executive directors, being Dr. Zhang Jing An, Mr. Paul Contomichalos and Dr. Wu Shou Yuan.

This announcement, for which the directors of the Company (the "Directors") collectively and individually accept responsibility, includes particulars given in compliance with the Rules Governing the Listing of securities of the Growth Enterprise Market of the Stock Exchange for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, conform that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respect and not misleading; (2) there are no other matters the omission of which would make any statement in all material respects and not misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable. This announcement will remain on the GEM website with the domain name of www.hkgem.com on the "Latest Company Announcements" page for at least 7days from the date of its posting and on

the Company's website at www.venturepharm.com.